Trial Profile
RIVET: Re-inventing Influenza Vaccine Efficacy Trials
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs VTP 100 (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms RIVET
- Sponsors Barinthus Biotherapeutics; Vaccitech
- 02 Oct 2017 Status changed from active, no longer recruiting to completed.
- 04 May 2017 New trial record